Dr. Ott on the CheckMate-032 Study in Gastric and GEJ Cancer
Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction cancer.
Patrick Ott, MD, PhD, clinical director, Melanoma Center, Center for Immuno-Oncology, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CheckMate-032 study in gastric and gastroesophageal junction (GEJ) cancer.
In this trial, 59 patients with either gastric or GEJ cancer were treated with nivolumab (Opdivo), most of which had received 2 or more prior lines of therapy.
The overall survival was promising, says Ott, with durable responses observed.
